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Abstract
Polo-like kinases (PLKs) play an important role in cell cycle progression, checkpoint control and mitosis. The high mitotic index
and chromosomal instability of advanced cancers suggest that PLK inhibitors may be an attractive therapeutic option for
presently incurable advanced neoplasias with systemic involvement, such as multiple myeloma (MM). We studied the PLK 1, 2, 3
inhibitor BI 2536 and observed potent (IC50,40 nM) and rapid (commitment to cell death ,24 hrs) in vitro activity against MM
cells in isolation, as well as in vivo activity against a traditional subcutaneous xenograft mouse model. Tumor cells in MM patients,
however, don’t exist in isolation, but reside in and interact with the bone microenvironment. Therefore conventional in vitro and
in vivo preclinical assays don’t take into account how interactions between MM cells and the bone microenvironment can
potentially confer drug resistance. To probe this question, we performed tumor cell compartment-specific bioluminescence
imaging assays to compare the preclinical anti-MM activity of BI 2536 in vitro in the presence vs. absence of stromal cells or
osteoclasts. We observed that the presence of these bone marrow non-malignant cells led to decreased anti-MM activity of BI
2536. We further validated these results in an orthotopic in vivo mouse model of diffuse MM bone lesions where tumor cells
interact with non-malignant cells of the bone microenvironment. We again observed that BI 2536 had decreased activity in this in
vivo model of tumor-bone microenvironment interactions highlighting that, despite BI 2536’s promising activity in conventional
assays, its lack of activity in microenvironmental models raises concerns for its clinical development for MM. More broadly,
preclinical drug testing in the absence of relevant tumor microenvironment interactions may overestimate potential clinical
activity, thus explaining at least in part the gap between preclinical vs. clinical efficacy in MM and other cancers.
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Introduction
One of the problems in oncology drug development today is the
discordance of highly promising in vitro and in vivo preclinical
results with the lack of efficacy observed in patients. Less than 8%
of agents that enter phase I clinical trials in cancer eventually
become FDA approved for the treatment of any tumor type [1].
Data from our group and others indicate that interaction of
malignant cells with their local microenvironment can confer drug
resistance, which may account for this gap between the preclinical
drug activity and clinical efficacy [2,3].
Polo-like kinases (PLKs) are particularly interesting targets in
cancer because of their role in cell cycle progression, checkpoint
control and mitosis [4,5]. Tumors with PLK overexpression are
associated more frequently with chromosomal instability, DNA
aneuploidy and centrosome amplification [6]. In addition, cancer
cells are more sensitive to PLK inhibition than normal cells [7]; and
PLK expression has been shown to be higher in cancer cells with a
high mitotic index [8]. In advanced multiple myeloma (MM),
malignant cells have a high mitotic index [9] and chromosomal
instability [10], suggesting that PLK inhibitors may be an attractive
therapeutic option for this presently incurable disease.
Here we evaluate the activity of the PLK 1, 2, 3 inhibitor BI
2536 in preclinical models of MM and investigate the role of the
microenvironment in modulating its anti-MM activity. We
observed potent anti-MM activity in traditional drug development
experiments, but decreased activity of BI 2536 in bone
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7microenvironmental models. Our results highlight that BI 2536
represents a compound with promising characteristics, but its lack
of activity in microenvironmental models of MM raises concerns
for its clinical development for this disease. These concerns are
compatible with the limited clinical activity that this agent has
shown so far in clinical trials in solid tumors, even though clinically
achievable concentrations exceed the levels needed for in vitro anti-
tumor activity based on conventional models. These models can
overestimate the drug activity because they do not incorporate
tumor-microenvironment interactions. More broadly, our study
provides a concrete example of the importance of preclinical
testing of investigational therapeutics in models that simulate how
the non-malignant accessory cells of the tumor microenvironment
may confer drug resistance.
Results and Discussion
Anti-MM activity of PLK inhibitor in vitro and in vivo in the
absence of bone microenvironmental interactions
Because of the activity of BI 2536 in other cancer models and the
role of PLKs in cell cycle regulation [4,5], we evaluated a panel of
MMcelllinesforsensitivitytoBI2536 (Fig.1a).Weobservedpotent
activity with IC50 values ,40 nM for the majority of cell lines,
including lines resistant to established anti-MM agents (e.g.
dexamethasone-resistant MM.1R). The BI 2536 concentrations
required for in vitro anti-MM activity are within its clinically
achievable levels [11]. These in vitro responses were rapid, requiring
,24 hrs of drug exposure to commit cells to death (Fig. 1b). Non-
malignant cells, such as HS-5 stromal cells, THLE-3 hepatocytes
and osteoclasts (OCs) had IC50 values .40 nM (Fig. 1c). The
potencyandrapidkineticsofBI2536activityarealso highlightedby
the cell cycle analysis (G2/M arrest, followed by increase sub-G0
events; Fig. 1d), rapid cleavage of caspase 3 and PARP within 8 hrs
of treatment (Fig. 1e) and formation of monopolar asters (Fig. 1f). In
a subcutaneous animal model, BI 2536 significantly suppressed
tumor burden (Fig. 1g) and prolonged survival (Fig. 1h), without
changes in body weight (Fig. 1i). These preclinical in vitro and in vivo
data are similar to those that provided in the past the framework for
further clinical development of BI 2536 in other neoplasias. These
experiments in other models, however, did not take intoaccount the
ability of the bone microenvironment to modulate drug activity.
Effects of the bone microenvironment on PLK inhibitor
activity in vitro and in vivo
Emerging literature indicates that the activity of different anti-
cancer agents can be modulated by the non-malignant accessory
cells of the microenvironment in which tumor cells are located [2].
We therefore recently developed an in vitro model, tumor cell
compartment-specific bioluminescence imaging (CS-BLI), which
allows high-throughput scalable evaluation of investigational
agents in co-cultures simulating the tumor-stromal interactions
[2]. This allows us to identify compounds with increased, as well as
others with deceased, antitumor activity in the presence of stromal
cells [2]. Importantly, we used of this in vitro co-culture platform
in tandem with our orthotopic animal models and validated in vivo
these observations in conditions which reflect the tumor
microenvironment and simulate the patient condition [2].
Based on this experience, we assessed the effect of the bone
microenvironment on the anti-MM activity of BI 2536. We first
tested the compound in vitro against MM cell lines cultured alone or
in the presence HS-5 stromal cells, differentiated OCs or primary
bone marrow stromal cells from MM patients. Drug activity was
selectively assessed using the CS-BLI assay. BI 2536 was less active
against MM.1S (Fig. 2a), OPM2 (Fig. 2b) and JJN3 (Fig. 2c) MM
cells in the presence of HS-5 stromal cells or differentiated OCs
compared to the absence of accessory cells.In addition,BI 2536 was
less active against MM.1S (Fig. 2d), OPM2 (Fig. 2e) and JJN3
(Fig. 2f) cells in the presence of patient stroma. The shift in IC50 in
the presence of accessory cells indicates a smaller difference in IC50
compared to stromal cells and hepatocytes, which suggests there
may be a reduced therapeutic window for this compound in the
presence of elements of the bone milieu.
In addition to our in vitro microenvironment assessment of BI
2536, we tested the compound in our in vivo orthotopic model of
diffuse myeloma lesions [12]. In this model, tumor cells home to the
bone in multiple sites, consistent with the clinical presentation of
myeloma in patients. We observed no significant activity of BI 2536
when administered at 50 mg/kg 2x weekly (Fig. 2g) and no
significant prolongation of survival in treated mice vs. vehicle
treated controls (Fig. 2h). Although this dose was higher than in the
s.c. model, we still did not observe significant toxicity, as evidenced
by the lack of weight loss in the BI 2536 treated mice compared to
vehicle-treatedcontrols(Fig.2i).The MM.1Scelllinemodelutilized
in our in vivo studies was one of the most drug-responsive cell lines in
vitro,however, itsinvivoresponseinthe s.c.model,butnotthe diffuse
bone model, illustrates that tumor cells highly sensitive to a given
drug in the absence of the bone microenvironment may become
more drug-resistant in its presence.
One of the biggest problems in oncology remains the low success
rate of translating preclinical results to effective clinical drugs. Among
the various reasons for this discrepancy, our data suggest that the
tumor microenvironment plays a role in decreasing anti-cancer drug
efficacy. PLK inhibitors such as BI 2536, although active against
tumors studied outside the context of their bone microenvironment,
are less active in models that take this interaction into account. The
application of both invitroand invivo modelsthatsimulatehowtumors
interact with the microenvironment in patients would improve the
prioritization of PLKs inhibitors, and other compounds, for further
development. Utilizing orthotopic invivo models, which include all the
elements of the local tumor microenvironment, in conjunction with
co-culture in vitro screening offers a better simulation of clinical
conditionthanconventionalmodels.Relyingexclusivelyonin vitro co-
culture assays, especially if supra-pharmacological doses and non-
relevant durations of exposure are used, may over-estimate the ability
of a given drug to overcome microenvironment-dependent drug
resistance. This may explain why prior studies using BI5236 at
2.5 mM (a dose higher than the Cmax in patients) did not detect in
vitro stroma-induced resistance of tumor cells[13].
Interestingly, multiple clinical trials of BI 2536 in solid tumors
[11,14,15,16] have shown limited objective clinical responses in
clinical trials, despite achievable levels of BI 2536 far exceeding
those showing in vitro activity in solid tumor models. This raises the
possibility that, similarly to our observations in MM models, solid
tumor cells may also exhibit a microenvironment-dependent
resistance to BI 2536. Furthermore, other clinical trials of agents
in the same class have shown limited clinical activity as well [17],
suggesting that the lack of clinical activity so far for this drug class
could be attributable in part to microenvironmental factors,
although further studies are warranted.
Although we observed microenvironment resistance to BI 2536 in
preclinical models, there may be subpopulations of MM patients who
may respond to this drug despite these microenvironment interac-
tions. To evaluate this we examined the gene expression data of
myeloma patients from the Dutch HOVON trial (N=320) for the
expression of PLKtranscripts. Weobserved that PLK1 (201429_at) is
expressed at higher levels in patients compared to the other PLK
isoforms (Fig. 3a). Comparing PLK1transcript (202240_at) in various
stages of disease, we observe a significantly higher expression level in
PLK Inhibitor Activity Influenced by Tumor Milieu
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premalignant monoclonal gammopathy of undetermined significance
(MGUS) (P,0.05) and a trend compared to MM patients, although
not statistically significant (Fig. 3b). Interestingly, we observed
significantly higher PLK1 transcript (37228_at) expression in the
proliferative (PR) subtype of MM compared to CD1 (cases with
CCND1 upregulation because of t(11;14) translocation), CD2 (cases
with CCND3 upregulation because of t(6;14) translocation), HY
(hyperdiploid MM),LB (‘‘Low Bone’’disease group,characterized by
low number of magnetic resonance imaging (MRI)–defined focal
bone lesions and low expression of DKK1), and MS (cases with
MMSET overexpression due to t(4;1;4) translocation) subtypes (1-
way ANOVA; p,0.0001; Dunn’s multiple comparison post-hoc tests
for each of the comparison between subtypes, p,0.05), but not
compared to the MF subtype (cases with overexpression of MAF/
MAFB)o fM Mp a t i e n t s( p .0.05; Fig. 3c). The PR subtype of MM is
the one that most closely resembles the molecular profiles of MM cell
lines [18], such as those evaluated in our study. This observation
suggests that PLK inhibition may still be an interesting putative
therapeutic approach for MM patients harboring a proliferative
transcriptional signature in their tumor cells. However, our
observations that BI 2536 is subject to microenvironment-dependent
drug resistance suggest that caution is warranted for further clinical
development in MM, even for patients of the PR subtype.
Figure 1. Activity of the small molecule PLK1, 2, and 3 inhibitor BI 2536 in preclinical models of MM in the absence of the bone
microenvironment. (A) BI 2536 (0–80 nM; 72 hrs) was tested against a panel of MM cell lines by MTT assay, the majority having IC50 values
,40 nM. (B) Dox40, OPM2, and MM.1S were evaluated by cell death commitment assay (0–24 hrs; 50 nM drug exposure, followed by 72 hrs of
culture in drug-free media). MM.1S and OPM2 (sensitive cell lines from panel A) required ,24 hr of exposure to BI 2536 to commit cells to death. In
contrast, up to 24 hr of drug exposure had no effect on Dox40 viability. (C) Non-malignant cells, including immortalized hepatocytes (THLE-3) and
stromal cells (HS-5), as well as osteoclasts (OC), were evaluated for sensitivity to BI 2536 (72 hrs) by MTT assay. All non-malignant cells tested remain
less sensitive to the drug than the majority of MM cell lines. (D) Cell cycle analysis of KMS18 cells exposed to BI 2536 (10 nM; 4–48 hrs) shows
pronounced increase in the G2/M events, followed by an increase in subG0/G1 events at later time points. (E) Western blot analysis revealed cleavage
of caspase 3 and PARP as early as 8 hrs of drug exposure (20 nM), indicating apoptotic cell death in KMS18 cells. Decreases in Akt, but not B-raf, were
observed in response to treatment. (F) MM.1S cells were exposed to 10 nM BI 2536 for 24 hrs, stained for a-tubulin (Red) and Hoechst (Blue) and
compared to non-treated controls. Treatment with BI 2536 caused an increase in monopolar aster formation as a result of the effects on cell cycle
progression and division. (G–I) Animal studies performed in a subcutaneous model of MM (n=9, control n=8, treated) showed significant
suppression of tumor burden (p=0.0005; panel G), prolongation of survival (p,0.0001; Kaplan-Meier & log rank test; panel H) and no significant
decrease in average body weight (panel I), consistent with lack of major toxicity. The transient decrease in average tumor burden of control mice is
due to the early death of some mice with high tumor burden (G).
doi:10.1371/journal.pone.0020226.g001
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into account tumor microenvironmental interactions, and therefore
may overestimate the clinical activity of investigational agents.
Incorporating the microenvironmental component into preclinical
studies may reconcile the discordance between preclinical and
clinical efficacy and thereby improve the bench to bedside
translation of effective therapies. In conclusion, BI 2536 is a less
attractive agent for development in MM based on our microenvi-
ronment data, unless further studies determine clinically applicable
methods to overcome this microenvironment-dependant resistance.
Materials and Methods
Compound
BI 2536 (CAS 755038-02-9, C28H39N7O3, MW 521.66) was
synthesized by published methods [19], characterized by
1Ha n d
13C
nuclear magnetic resonance, solubilized in DMSO (in vitro) or 0.1N
HCl/0.9% NaCl (in vivo) and used as indicated in figure legends.
Cell viability assays
Viability of MM cell lines, THLE-3 hepatocytes, and HS-5
stromal cells was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrasodium bromide (MTT; Chemicon International)
colorimetric assay, as previously published [20], and viability of
osteoclasts (OC) was measured by CellTiterGlo assay (CTG;
Promega) for 72 hrs. In vitro osteoclast differentiation from normal
donor PBMCs was performed as previously described [21]. For
cell death commitment assays, MM cells were exposed to BI 2536
(20 nM) for up to 24 hrs, washed and incubated in drug-free
medium for 3 days and quantified by MTT assay. For co-culture
experiments, tumor compartment specific-bioluminescence imag-
ing (CS-BLI) was used to selectively detect tumor cell viability[2].
Cell cycle analysis
KMS18 cells treated with BI 2536 (20 nM; 0–48 hrs) were
stained using propidium iodide/RNase A (Sigma) following 70%
EtOH fixation, passed through a flow cytometer (Beckman
Coulter) and analyzed using FlowJo software (Treestar).
Immunoblotting and immunoflourescence studies
KMS18 cells were treated with BI 2536 (20 nM) for 0–48 hrs
and immunoblotted, as previously described [22]. For immuno-
flourescence studies, cells were fixed in 2% Paraformaldehyde;
resuspended in 5% Goat Serum (GS) in PHEM buffer and
Figure 2. Anti-MM activity of BI 2536 is attenuated in preclinical models incorporating MM cell interaction with the bone
microenvironment. (A–C) MM.1S, OPM2 and JJN3 cells were tested in the presence and absence of HS-5 stromal cells and differentiated OC of the
bone. Co-culture with stromal cells and OC decreases the sensitivity of MM cells to BI 2536. (D–F) Stromal cells isolated from MM patients also
decrease the sensitivity of MM.1S, OPM2, and JJN3 cells to BI 2536. (G–I) Animal studies performed in the MM model of diffuse lesions in the bone
(n=8, control n=7, treated) did not show significant changes in tumor burden (p=NS; panel G), prolongation of survival (panel H) or decrease in
average body weight (p=NS; panel I).
doi:10.1371/journal.pone.0020226.g002
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GS/PHEM and incubated with primary/secondary antibodies
and Hoechst counter-stain; mounted with Vinol mounting media
and imaged using a Nikon E800 Eclipse Microscope (Nikon,
Japan) and Cool Snap HQ2 Camera (Photometrics).
In vivo anti-tumor activity of BI 2536
Sublethally irradiated (150 rads) CB17-SCID mice were
injected with MM1.S-GFP/luc cells subcutaneously (2.5610
6)o r
i.v. (10
6). Following engraftment, mice received i.v. BI 2536
(40 mg/kg, s.c. model or 50 mg/kg i.v. model 2x weekly). Mice
were monitored regularly for changes in tumor burden (calipers
for subcutaneous model and Xenogen IVIS system for i.v. model),
changes in body weight and sacrificed in accordance with
institutional guidelines. Mice were housed in the Animal Research
Facility of the Dana-Farber Cancer Institute and experiments were
performed in accordance with protocol approved by the Dana-
Farber Cancer Institute Animal Care and Use Committee
(ACUC) (protocol #04-111) and in accordance with relevant
national and international guidelines, including steps taken to
ameliorate any suffering of animals.
Expression of PLK transcripts in MM patient cells. Gene
expression data from publicly available Gene Expression Omnibus
(GEO) datasets (accession numbers GSE19784, GSE2113,
GSE2658 and GSE8546) were downloaded and analyzed
through Oncomine 4.4 (for datasets GSE2658 and GSE8546) or
directly from GEO (datasets GSE19784 and GSE2113). These
datasets included profiles of CD138+ myeloma cells from patients
enrolled in the Dutch HOVON trial (N=320, GSE19784) [23];
CD138+ plasma cells from patients with monoclonal gammopathy
of undetermined significance (MGUS), myeloma or plasma cell
leukemia (7, 39 and 6 cases respectively, N=52 total, GSE2113)
Figure 3. Clinical relevance of PLK in patients from the HOVON myeloma dataset. (A) Myeloma patient samples from the Dutch HOVON
trial (N=320, GSE19784) were evaluated for the expression of PLK transcripts. PLK1 (201429_at) is expressed at higher levels in patients compared to
the other PLK isoforms. (B) We observe a significantly higher expression level of PLK1 transcript (202240_at) in PCL patients compared to MGUS
(P,0.05) and a trend for higher expression in MM vs. MGUS patients in the GSE2113 dataset; (C) Expression of PLK1 transcript is higher among newly
diagnosed MM patients which are classified to have a proliferative (PR) transcriptional signature in their CD138+ tumor cell compared to other gene
expression-based molecular subtypes of MM, specifically the CD1, CD2, HY, LB, and MS subtypes (GSE2658 dataset). (D) The expression of PLK1
transcript is higher in MM patients when disease recurrence is observed compared to pre-treatment samples (GSE8546 dataset).
doi:10.1371/journal.pone.0020226.g003
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patients (GSE2658) [25]; and CD138+ myeloma cells from 174
cases prior to initiation of therapy vs. 55 cases after disease
recurrence (N=229 total, GSE8546) [26]. Using one-way
ANOVA analysis, we evaluated the absolute expression of
various probes for PLK1, 2, 3 and 4 (GSE19784); the
differences in expression of PLK1 transcript in MGUS, MM
and PCL (GSE2113); as well as the differences in log2-transformed
median-centered transcript levels, in the GSE19784 dataset [23]
for PLK1 in various molecularly defined subtypes of MM [25].
The difference in log2-transformed median-centered transcript
levels of PLK1 in primary vs recurrent disease (GSE8546) was
evaluated by unpaired t-test. Statistical analyses were performed
with Prism 5 software (Graphpad).
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